US006638922B2

(12) **United States Patent**
Ashley et al.

(10) **Patent No.: US 6,638,922 B2**
(45) **Date of Patent: Oct. 28, 2003**

(54) **4-DEDIMETHYLAMINOTETRACYCLINE DERIVATIVES**

(75) Inventors: **Robert Ashley**, Newton, PA (US); **Joseph J. Hlavka**, Suffern, NY (US)

(73) Assignee: **CollaGenex Pharmaceuticals Incorporated**, Newtown, PA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/911,861**

(22) Filed: **Jul. 24, 2001**

(65) **Prior Publication Data**

US 2002/0160987 A1 Oct. 31, 2002

(Under 37 CFR 1.47)

Related U.S. Application Data

(63) Continuation-in-part of application No. 09/573,654, filed on May 18, 2000, now Pat. No. 6,506,704, which is a continuation-in-part of application No. 09/479,604, filed on Jan. 7, 2000, now abandoned, which is a continuation-in-part of application No. 09/195,013, filed on Nov. 18, 1998, now abandoned.

(51) **Int. Cl.**[7] **A61K 31/65**; C07C 237/26
(52) **U.S. Cl.** **514/152**; 552/203
(58) **Field of Search** 552/203; 514/152

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,786,077 A		3/1957	Stephens, Jr.	
2,970,087 A	*	1/1961	Beck et al.	195/80
2,976,318 A		3/1961	Blackwood	
3,026,248 A		3/1962	Noseworthy et al.	
3,029,284 A		4/1962	Gordon	
3,036,120 A		5/1962	Hammer et al.	
3,042,716 A		7/1962	Blackwood et al.	
3,043,875 A	*	7/1962	Beereboom et al.	260/559
3,047,626 A		7/1962	Stephens, Jr. et al.	
3,069,467 A		12/1962	Beereboom et al.	
3,109,007 A		10/1963	Blackwood et al.	
3,146,265 A		8/1964	Scott et al.	
3,159,675 A		12/1964	Esse et al.	
3,239,499 A		3/1966	Rennhard et al.	
3,265,732 A		8/1966	Miller et al.	
3,304,227 A		2/1967	Loveless	
3,345,370 A		10/1967	Esse et al.	
3,359,160 A		12/1967	Gordon	
3,428,679 A		2/1969	Rondelet	
3,502,660 A		3/1970	Butler et al.	
3,502,696 A		3/1970	Conover	
3,509,184 A		4/1970	Conover et al.	
3,515,731 A		6/1970	Conover	
3,609,188 A		9/1971	Esse	
3,622,627 A		11/1971	Blackwood et al.	
3,697,552 A		10/1972	Conover et al.	
3,772,363 A		11/1973	Conover et al.	
3,824,285 A		7/1974	Blackwood et al.	
3,829,453 A		8/1974	Conover et al.	
3,849,493 A		11/1974	Conover et al.	
4,419,365 A		12/1983	McLachlan	
4,704,383 A		11/1987	McNamara et al.	
4,925,833 A		5/1990	McNamara et al.	
5,122,519 A	*	6/1992	Ritter	514/152
5,223,248 A		6/1993	McNamara et al.	
5,308,839 A		5/1994	Golub et al.	
5,321,017 A		6/1994	Golub et al.	
5,371,076 A	*	12/1994	Lee et al.	514/152
5,459,135 A		10/1995	Golub et al.	
5,523,297 A		6/1996	Pruzanski et al.	
5,529,990 A		6/1996	Hlavka et al.	
5,532,227 A		7/1996	Golub et al.	
5,563,130 A		10/1996	Backer et al.	
5,567,693 A		10/1996	Backer et al.	
5,574,026 A		11/1996	Backer et al.	
5,773,430 A		6/1998	Simon et al.	
5,789,395 A		8/1998	Amin et al.	
5,849,290 A		12/1998	Brown et al.	
5,919,775 A		7/1999	Amin et al.	
5,998,390 A		12/1999	Ramamurthy et al.	

FOREIGN PATENT DOCUMENTS

WO	WO 94/19493	9/1994
WO	WO 99/30720	6/1999

OTHER PUBLICATIONS

Forloni et al. "Anti–amyloidogenic activity of tetracyclines: studies in vitro," *FEBS Letters* 487:404–407 (2001).

Tikka et al. "Minocycline Provides Neuroprotection Against N–Methyl–D–aspartate Neurotoxicity by Inhibiting Microglia," *The Journal of Immunology,* 166:7527–7533 (2001).

Tikka et al. "Minocycline, a Tetracycline Derivative, is Neuroprotective aganist Excitoxicity by Inhibiting Activation and Proliferation of Microglia," *The Journal of Neuroscience,* 21(8):2580–2588 (2001).

Koza "Synthesis of 7–Substituted Tetracycline Derivatives," *Organic Letters;* 2(6):815–817 (2000).

Chen et al. "Minocycline inhibits caspase–1 and caspase–3 expression and delays mortality in a transgenic mouse model of Huntington disease," *Nature Medicine,* 6(7):797–801 (2000).

(List continued on next page.)

Primary Examiner—Barbara P. Badio
(74) *Attorney, Agent, or Firm*—Hoffman & Baron, LLP

(57) **ABSTRACT**

The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted with aryl, alkenyl, or alkynyl groups. The 7, 8, and/or 9 positions and methods for preparing such compounds. Other tetracycline compounds include the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N—NH-Alkyl group substituted at the C4 position as well as C2 Mannich derivatives. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified tetracycline compounds.

10 Claims, 1 Drawing Sheet